CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Virulizin®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00040092
NCT00040092Phase 3Completed
CompareCT.gov

A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer

Aptose Biosciences Inc.·interventional·Posted Jun 20, 2002·Updated Jan 7, 2008

In Brief

A Phase 3 clinical trial evaluating Virulizin® for Pancreatic Cancer. Completed.

Detailed Summary

Virulizin is an immunotherapy drug preparation that is thought to stimulate the patient's immune system, which in turn may slow the growth of tumors. It is presented in vials as a sterile preparation for IM injection. The purpose of the trial is to investigate if Virulizin in combination with gemcitabine provides better efficacy than gemcitabine alone (with placebo) against pancreatic cancer.Virulizin® efficacy will continue to be assessed if chemotherapy is changed to 5-Fluorouracil.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2002
Enrollment StartJul 1, 2002
Primary CompletionJul 1, 2005
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 24.0 years ago

Interventions

Virulizin®drug